To our knowledge, the findings of this study provide some of the first evidence that, among individuals with T2D, the use of GLP-1 RAs was associated with a lower risk of sight-threatening complications, including PDR, DME, and neovascular glaucoma, despite a marginally increased incidence of any DR. This evidence concerns the gene GCG and type 2 diabetes mellitus.